Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lerodalcibep versus placebo in children with heterozygous familial hypercholesterolemia
PACTR202605715221380Phase 3Not yet recruiting
- Sponsor
- LIB Therapeutics
- Start
- Jul 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lerodalcibep in heterozygous familial hypercholesterolemia (HeFH), sponsored by LIB Therapeutics. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
lerodalcibep
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on PACTR202605715221380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605715221380.